Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis

Gagelmann, Nico; Bishop, Michael; Ayuk, Francis; Bethge, Wolfgang; Glass, Bertram; Sureda, Anna; Pasquini, Marcelo C.; Kröger, Nicolaus

doi:10.1016/j.jtct.2024.01.074

Transplantation and Cellular Therapy

2024

DOI: 10.1016/j.jtct.2024.01.074

|View full text |Cite

Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis

Nico Gagelmann,

Michael Bishop,

Francis Ayuk

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Tracking non-relapse mortality after CAR T cell therapy

Blumenberg,

Maus

2024

Nat Med

View full text Add to dashboard Cite

Tracking non-relapse mortality after CAR T cell therapy

Blumenberg,

Maus

2024

Nat Med

View full text Add to dashboard Cite

The cardiotoxic effects of CAR‐T cell therapy: An updated systematic review and meta‐analysis

Mazetto,

Monteiro,

Bulhões

et al. 2024

European J of Haematology

View full text Add to dashboard Cite

BackgroundChimeric antigen receptor T‐cell (CAR‐T) therapy has shown promise in treating hematologic malignancies, yet its potential cardiotoxic effects require thorough investigation.ObjectivesWe aim to conduct a systematic review and meta‐analysis to examine the cardiotoxic effects of CAR‐T therapy in adults with hematologic malignancies.MethodsWe searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for studies reporting cardiovascular outcomes, such as arrhythmias, heart failure, and reduced left ventricle ejection fraction (LVEF).ResultsOur analysis of 20 studies involving 4789 patients revealed a 19.68% incidence rate of cardiovascular events, with arrhythmias (7.70%), heart failure (5.73%), and reduced LVEF (3.86%) being the most prevalent. Troponin elevation was observed in 23.61% of patients, while NT‐Pro‐BNP elevation was observed in 9.4. Subgroup analysis showed higher risks in patients with pre‐existing conditions, such as atrial arrhythmia (OR 3.12; p < .001), hypertension (OR 1.85; p = .002), previous heart failure (OR 3.38; p = .003), and coronary artery disease (OR 2.80; p = .003).ConclusionVigilant cardiovascular monitoring is crucial for patients undergoing CAR‐T therapy to enhance safety and treatment efficacy.Novelty Statements.

show abstract

Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas

Bender,

Damodharan,

Capitini

et al. 2024

Blood Advances

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis

Cited by 4 publications

References 55 publications

Tracking non-relapse mortality after CAR T cell therapy

Tracking non-relapse mortality after CAR T cell therapy

The cardiotoxic effects of CAR‐T cell therapy: An updated systematic review and meta‐analysis

Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas

Contact Info

Product

Resources

About